{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T10:32:00Z","timestamp":1793442720524,"version":"4.5.0"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["RS-2024-00395923"],"award-info":[{"award-number":["RS-2024-00395923"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jconrel.2026.115431","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:22:19Z","timestamp":1791008539000},"page":"115431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PB","title":["Delivery architectures for oligonucleotide therapeutics in genetic and rare diseases: GalNAc-based hepatocyte targeting and extrahepatic translation"],"prefix":"10.1016","volume":"399","author":[{"given":"Chan Hyeok","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunjun","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang Hyeok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Hee","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Uk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Woo","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangmin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jconrel.2026.115431_bb0005","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115431_bb0010","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115431_bb0015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41573-019-0049-9","article-title":"Therapies for rare diseases: therapeutic modalities, progress and challenges ahead","volume":"19","author":"Tambuyzer","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"17","key":"10.1016\/j.jconrel.2026.115431_bb0020","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-customized oligonucleotide therapy for a rare genetic disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115431_bb0025","series-title":"IND Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Clinical Recommendations","author":"U.S. Food and Drug Administration","year":"2021"},{"issue":"6669","key":"10.1016\/j.jconrel.2026.115431_bb0030","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jconrel.2026.115431_bb0035","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115431_bb0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115431_bb0045","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"issue":"49","key":"10.1016\/j.jconrel.2026.115431_bb0050","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115431_bb0055","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","article-title":"Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates","volume":"26","author":"Foster","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115431_bb0060","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2015.02.022","article-title":"Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications","volume":"203","author":"D\u2019Souza","year":"2015","journal-title":"J. Control. Release"},{"issue":"17","key":"10.1016\/j.jconrel.2026.115431_bb0065","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/gt.2008.60","article-title":"The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer","volume":"15","author":"Wisse","year":"2008","journal-title":"Gene Ther."},{"issue":"21","key":"10.1016\/j.jconrel.2026.115431_bb0070","doi-asserted-by":"crossref","first-page":"11827","DOI":"10.1093\/nar\/gkaa670","article-title":"Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates","volume":"48","author":"Brown","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2026.115431_bb0075","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.jconrel.2026.115431_bb0080","series-title":"Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO\u00ae (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)","author":"Arrowhead Pharmaceuticals, Inc","year":"2025"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115431_bb0085","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/21593337261435980","article-title":"The approval of Redemplo for familial chylomicronemia syndrome and the many Flavors of GalNAc-oligonucleotides","volume":"36","author":"Alterman","year":"2026","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.jconrel.2026.115431_bb0090","series-title":"RIVFLOZA, Nedosiran Injection, Prescribing Information","author":"U.S. Food and Drug Administration","year":"2025"},{"key":"10.1016\/j.jconrel.2026.115431_bb0095","series-title":"QFITLIA, Fitusiran Injection, Prescribing Information","author":"U.S. Food and Drug Administration","year":"2025"},{"key":"10.1016\/j.jconrel.2026.115431_bb0100","series-title":"REDEMPLO, Plozasiran Injection, Prescribing Information","author":"U.S. Food and Drug Administration","year":"2025"},{"key":"10.1016\/j.jconrel.2026.115431_bb0105","series-title":"AMVUTTRA, Vutrisiran Injection, Prescribing Information","author":"U.S. Food and Drug Administration","year":"2025"},{"key":"10.1016\/j.jconrel.2026.115431_bb0110","series-title":"GIVLAARI, Givosiran Injection, Prescribing Information","author":"U.S. Food and Drug Administration","year":"2025"},{"key":"10.1016\/j.jconrel.2026.115431_bb0115","series-title":"OXLUMO, Lumasiran Injection, Prescribing Information","author":"U.S. Food and Drug Administration","year":"2025"},{"key":"10.1016\/j.jconrel.2026.115431_bb0120","series-title":"LEQVIO, Inclisiran Injection, Prescribing Information","author":"U.S. Food and Drug Administration","year":"2026"},{"key":"10.1016\/j.jconrel.2026.115431_bb0125","series-title":"WAINUA, Eplontersen Injection, Prescribing Information","author":"U.S. Food and Drug Administration","year":"2025"},{"key":"10.1016\/j.jconrel.2026.115431_bb0130","series-title":"TRYNGOLZA, Olezarsen Injection, Prescribing Information","author":"U.S. Food and Drug Administration","year":"2024"},{"key":"10.1016\/j.jconrel.2026.115431_bb0135","series-title":"DAWNZERA, Donidalorsen Injection, Prescribing Information","author":"U.S. Food and Drug Administration","year":"2025"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115431_bb0140","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1152\/physrev.1995.75.3.591","article-title":"The asialoglycoprotein receptor: relationships between structure, function, and expression","volume":"75","author":"Stockert","year":"1995","journal-title":"Physiol. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115431_bb0145","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.jconrel.2026.115431_bb0150","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.omtn.2016.12.003","article-title":"Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics","volume":"6","author":"Huang","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"8","key":"10.1016\/j.jconrel.2026.115431_bb0155","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115431_bb0160","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41587-019-0205-0","article-title":"A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system","volume":"37","author":"Alterman","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115431_bb0165","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","article-title":"Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates","volume":"40","author":"Brown","year":"2022","journal-title":"Nat. Biotechnol."},{"issue":"S5","key":"10.1016\/j.jconrel.2026.115431_bb0170","doi-asserted-by":"crossref","DOI":"10.1002\/alz70859_097989","article-title":"Multiple-dose results from an ongoing phase 1 study of Mivelsiran, an investigational RNA interference therapeutic targeting amyloid-Beta precursor protein for Alzheimer\u2019s disease","volume":"21","author":"Cohen","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jconrel.2026.115431_bb0175","series-title":"A Study to Evaluate ALN-HTT02 in Adult Patients with Huntington\u2019s Disease","author":"Alnylam Pharmaceuticals","year":"2024"},{"issue":"8","key":"10.1016\/j.jconrel.2026.115431_bb0180","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkag287","article-title":"Divalent siRNA for prion disease","volume":"54","author":"Gentile","year":"2026","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2026.115431_bb0185","series-title":"A Phase 2 Trial of ALN-APP in Patients with Cerebral Amyloid Angiopathy","author":"Alnylam Pharmaceuticals","year":"2024"},{"key":"10.1016\/j.jconrel.2026.115431_bb0190","author":"Broad Institute of MIT and Harvard and National Institute of Neurological Disorders and Stroke (NINDS)"},{"key":"10.1016\/j.jconrel.2026.115431_bb0195","series-title":"Dyne Therapeutics Announces Upcoming Presentations across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference","author":"Dyne Therapeutics","year":"2026"},{"key":"10.1016\/j.jconrel.2026.115431_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2016.06.036","article-title":"Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles","volume":"237","author":"Sugo","year":"2016","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.jconrel.2026.115431_bb0205","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJMoa2407326","article-title":"An antibody-oligonucleotide conjugate for myotonic dystrophy type 1","volume":"394","author":"Johnson","year":"2026","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115431_bb0210","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s43856-025-00733-w","article-title":"FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models","volume":"5","author":"Weeden","year":"2025","journal-title":"Commun. Med. (Lond.)"},{"issue":"12","key":"10.1016\/j.jconrel.2026.115431_bb0215","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1093\/nar\/gkad415","article-title":"Targeted tissue delivery of RNA therapeutics using antibody-oligonucleotide conjugates (AOCs)","volume":"51","author":"Malecova","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115431_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102357","article-title":"Local CpG-Stat3 siRNA treatment improves antitumor effects of immune checkpoint inhibitors","volume":"35","author":"Zhang","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2026.115431_bb0225","series-title":"CpG-STAT3 siRNA CAS3\/SS3 and Localized Radiation Therapy for the Treatment of Relapsed\/Refractory B-Cell NHL","author":"City of Hope Medical Center","year":"2021"},{"key":"10.1016\/j.jconrel.2026.115431_bb0230","series-title":"Considerations for the Use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause","author":"U.S. Food and Drug Administration","year":"2026"},{"key":"10.1016\/j.jconrel.2026.115431_bb0235","series-title":"Platform Technology Designation Program for Drug Development","author":"U.S. Food and Drug Administration","year":"2024"},{"issue":"7299","key":"10.1016\/j.jconrel.2026.115431_bb0240","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nature09039","article-title":"Structural basis for 5\u2032-nucleotide base-specific recognition of guide RNA by human AGO2","volume":"465","author":"Frank","year":"2010","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115431_bb0245","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1261\/rna.5239604","article-title":"In vivo activity of nuclease-resistant siRNAs","volume":"10","author":"Layzer","year":"2004","journal-title":"RNA"},{"issue":"11","key":"10.1016\/j.jconrel.2026.115431_bb0250","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1093\/nar\/23.11.2019","article-title":"Characterization of fully 2\u2032-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity","volume":"23","author":"Cummins","year":"1995","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2026.115431_bb0255","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/jm049167j","article-title":"Fully 2\u2019-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA","volume":"48","author":"Allerson","year":"2005","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115431_bb0260","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1089\/nat.2014.0506","article-title":"Phosphorothioates, essential components of therapeutic oligonucleotides","volume":"24","author":"Eckstein","year":"2014","journal-title":"Nucleic Acid Ther."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115431_bb0265","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/cbic.201600130","article-title":"5\u2032-(E)-Vinylphosphonate: a stable phosphate mimic can improve the RNAi activity of siRNA-GalNAc conjugates","volume":"17","author":"Parmar","year":"2016","journal-title":"Chembiochem"},{"issue":"13","key":"10.1016\/j.jconrel.2026.115431_bb0270","doi-asserted-by":"crossref","first-page":"7581","DOI":"10.1093\/nar\/gkx507","article-title":"5\u0384-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo","volume":"45","author":"Haraszti","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115431_bb0275","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41467-018-02989-4","article-title":"Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity","volume":"9","author":"Janas","year":"2018","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115431_bb0280","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1093\/nar\/gkac539","article-title":"From bench to bedside: improving the clinical safety of GalNAc-siRNA conjugates using seed-pairing destabilization","volume":"50","author":"Schlegel","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115431_bb0285","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/cbic.201500023","article-title":"Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo","volume":"16","author":"Rajeev","year":"2015","journal-title":"Chembiochem"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115431_bb0290","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1038\/s41467-024-45609-0","article-title":"Structural optimization of siRNA conjugates for albumin binding achieves effective MCL1-directed cancer therapy","volume":"15","author":"Hoogenboezem","year":"2024","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115431_bb0295","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/s41551-025-01376-x","article-title":"siRNA conjugate with high albumin affinity and degradation resistance for delivery and treatment of arthritis in mice and guinea pigs","volume":"9","author":"Colazo","year":"2025","journal-title":"Nat. Biomed. Eng."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115431_bb0300","doi-asserted-by":"crossref","first-page":"11031","DOI":"10.3390\/cimb46100655","article-title":"Peptide-oligonucleotide conjugation: chemistry and therapeutic applications","volume":"46","author":"Malinowska","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.jconrel.2026.115431_bb0305","author":"SAREPTA therapeutics"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115431_bb0310","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1089\/nat.2019.0794","article-title":"Lipid conjugates enhance endosomal release of antisense oligonucleotides into cells","volume":"29","author":"Wang","year":"2019","journal-title":"Nucleic Acid Ther."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115431_bb0315","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115431_bb0320","series-title":"ONPATTRO, Patisiran Lipid Complex Injection, Prescribing Information","author":"U.S. Food and Drug Administration","year":"2018"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115431_bb0325","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/nar\/gkj439","article-title":"Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging","volume":"34","author":"Bartlett","year":"2006","journal-title":"Nucleic Acids Res."},{"issue":"24","key":"10.1016\/j.jconrel.2026.115431_bb0330","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic Givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.jconrel.2026.115431_bb0335","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.jconrel.2026.115431_bb0340","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of Inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115431_bb0345","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115431_bb0350","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial","volume":"10","author":"Srivastava","year":"2023","journal-title":"Lancet Haematol."},{"issue":"10386","key":"10.1016\/j.jconrel.2026.115431_bb0355","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115431_bb0360","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115431_bb0365","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.kint.2022.07.025","article-title":"PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2","volume":"103","author":"Baum","year":"2023","journal-title":"Kidney Int."},{"key":"10.1016\/j.jconrel.2026.115431_bb0370","series-title":"Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease","author":"Alnylam Pharmaceuticals, Inc","year":"2026"},{"key":"10.1016\/j.jconrel.2026.115431_bb0375","author":"Alnylam"},{"issue":"760","key":"10.1016\/j.jconrel.2026.115431_bb0380","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi2245","article-title":"Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier","volume":"16","author":"Barker","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115431_bb0385","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/s41587-024-02487-7","article-title":"Intravenous administration of blood-brain barrier-crossing conjugates facilitate biomacromolecule transport into central nervous system","volume":"43","author":"Wang","year":"2025","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115431_bb0390","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20131660","article-title":"Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants","volume":"211","author":"Bien-Ly","year":"2014","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115431_bb0395","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12987-025-00643-y","article-title":"The effects of dose, valency, and affinity on TfR-mediated brain delivery in vivo","volume":"22","author":"Bonvicini","year":"2025","journal-title":"Fluids Barriers CNS"},{"issue":"183","key":"10.1016\/j.jconrel.2026.115431_bb0400","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005338","article-title":"Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier","volume":"5","author":"Couch","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.115431_bb0405","author":"Avidity Biosciences"},{"key":"10.1016\/j.jconrel.2026.115431_bb0410","series-title":"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1","year":"2024"},{"key":"10.1016\/j.jconrel.2026.115431_bb0415","author":"Novartis"},{"issue":"7","key":"10.1016\/j.jconrel.2026.115431_bb0420","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkag301","article-title":"Development of a DUX4-targeting antibody oligonucleotide conjugate as a therapy for FSHD","volume":"54","author":"Malecova","year":"2026","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2026.115431_bb0425","author":"Avidity Biosciences"},{"key":"10.1016\/j.jconrel.2026.115431_bb0430","series-title":"Novartis Delpacibart Braxlosiran (del-brax) Phase I\/II study in Facioscapulohumeral Muscular Dystrophy (FSHD) Meets Primary Biomarker Endpoint","author":"Novartis","year":"2026"},{"key":"10.1016\/j.jconrel.2026.115431_bb0435","series-title":"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)","year":"2025"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115431_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102751","article-title":"Design of bifunctional RNA-binding compounds that can modulate siRNA hydrophobicity for deep penetration and gene silencing in the retina","volume":"36","author":"Mao","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2026.115431_bb0445","author":"ProQR"},{"key":"10.1016\/j.jconrel.2026.115431_bb0450","article-title":"RNA-based therapies in inherited retinal diseases","volume":"14","author":"Girach","year":"2022","journal-title":"Ther. Adv. Ophthalmol."},{"key":"10.1016\/j.jconrel.2026.115431_bb0455","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jconrel.2020.11.005","article-title":"Pulmonary siRNA delivery for lung disease: review of recent progress and challenges","volume":"330","author":"Ding","year":"2021","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115431_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.104076","article-title":"Dry powder inhalation of siRNA therapeutics: emerging strategies for pulmonary gene silencing","volume":"115","author":"Lu","year":"2026","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115431_bb0465","series-title":"A Phase 1\/2a Study Evaluating the Effects of ARO-RAGE Inhalation Solution in Healthy Subjects and Patients with Inflammatory Lung Disease","author":"Arrowhead Pharmaceuticals, Inc","year":"2022"},{"issue":"Supplement 1","key":"10.1016\/j.jconrel.2026.115431_bb0470","first-page":"A1376","article-title":"A first-in-human study of ARO-RAGE, a novel inhaled RNA-interference therapy for asthma","volume":"209","author":"O\u2019Carroll","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2026.115431_bb0475","series-title":"A Randomized, Double-blind, Placebo-controlled Phase 2a Study of ARO-RAGE Inhalation Solution to Assess Efficacy on Small Airway Dysfunction in Allergen-induced Mild Asthma (ARORAGE-2001)","author":"Arrowhead Pharmaceuticals, Inc","year":"2025"},{"key":"10.1016\/j.jconrel.2026.115431_bb0480","series-title":"A Phase 1\/2a Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-ENaC in Normal Healthy Volunteers and Safety, Tolerability and Efficacy in Patients with Cystic Fibrosis","author":"Arrowhead Pharmaceuticals, Inc","year":"2020"},{"key":"10.1016\/j.jconrel.2026.115431_bb0485","series-title":"Arrowhead Pauses ARO-ENaC Phase 1\/2 Clinical Study","author":"Arrowhead Pharmaceuticals, Inc","year":"2021"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115431_bb0490","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.kint.2015.11.007","article-title":"Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease","volume":"89","author":"Nielsen","year":"2016","journal-title":"Kidney Int."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115431_bb0495","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1016\/j.ymthe.2024.10.020","article-title":"Efficient and selective kidney targeting by chemically modified carbohydrate conjugates","volume":"32","author":"Kumar","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115431_bb0500","series-title":"Judo Bio\u2019s Megalin-STRIKERs Achieve First Demonstration of Functional Pharmacodynamic Effects from Kidney Selective Gene Silencing in Non-Human Primates","author":"Judo Bio","year":"2025"},{"key":"10.1016\/j.jconrel.2026.115431_bb0505","series-title":"Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity","author":"Arrowhead Pharmaceuticals, Inc.","year":"2025"},{"key":"10.1016\/j.jconrel.2026.115431_bb0510","series-title":"Arrowhead Pharmaceuticals Initiates Phase 1\/2a Study of ARO-ALK7 for the Treatment of Obesity","author":"Arrowhead Pharmaceuticals, Inc","year":"2025"},{"key":"10.1016\/j.jconrel.2026.115431_bb0515","series-title":"A Phase 1\/2A Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-ALK7 in Adult Volunteers with Obesity with and Without Type 2 Diabetes Mellitus","author":"Arrowhead Pharmaceuticals, Inc","year":"2025"},{"key":"10.1016\/j.jconrel.2026.115431_bb0520","series-title":"Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition","author":"Arrowhead Pharmaceuticals, Inc","year":"2026"},{"issue":"Suppl. 67","key":"10.1016\/j.jconrel.2026.115431_bb0525","article-title":"A lung-targeted RNAi therapeutics delivery platform compatible with subcutaneous (s.c.) administration mediates pulmonary RAGE silencing in rodents and nonhuman primates","volume":"62","author":"Kasahara","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115431_bb0530","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1053\/j.gastro.2024.06.028","article-title":"Fazirsiran for adults with alpha-1 antitrypsin deficiency liver disease: a phase 2 placebo controlled trial (SEQUOIA)","volume":"167","author":"Clark","year":"2024","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jconrel.2026.115431_bb0535","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2205416","article-title":"Fazirsiran for liver disease associated with alpha(1)-antitrypsin deficiency","volume":"387","author":"Strnad","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115431_bb0540","series-title":"Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein","author":"Takeda","year":"2023"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115431_bb0545","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1038\/s41467-022-33061-x","article-title":"Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington\u2019s disease models","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat. Commun."},{"issue":"21","key":"10.1016\/j.jconrel.2026.115431_bb0550","doi-asserted-by":"crossref","first-page":"9634","DOI":"10.1093\/nar\/gkt725","article-title":"Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS","volume":"41","author":"Ostergaard","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115431_bb0555","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/18796397251337000","article-title":"Huntington\u2019s disease clinical trials update: March 2025","volume":"14","author":"Farag","year":"2025","journal-title":"J. Huntington\u2019s Dis."},{"issue":"23","key":"10.1016\/j.jconrel.2026.115431_bb0560","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMc2300400","article-title":"Tominersen in adults with manifest Huntington\u2019s disease","volume":"389","author":"McColgan","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115431_bb0565","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115431_bb0570","series-title":"Tofersen (Qalsody): Use of a Surrogate Endpoint to Demonstrate Substantial Evidence of Effectiveness for an Accelerated Approval","author":"U.S. Food and Drug Administration","year":"2024"},{"key":"10.1016\/j.jconrel.2026.115431_bb0575","author":"n-Lorem Foundation"},{"issue":"9","key":"10.1016\/j.jconrel.2026.115431_bb0580","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jama.2024.0728","article-title":"RNA interference with zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial","volume":"331","author":"Bakris","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115431_bb0585","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jama.2025.6681","article-title":"Add-on treatment with zilebesiran for inadequately controlled hypertension: the KARDIA-2 randomized clinical trial","volume":"334","author":"Desai","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2026.115431_bb0590","author":"Alnylam"},{"issue":"20","key":"10.1016\/j.jconrel.2026.115431_bb0595","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115431_bb0600","series-title":"Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial","author":"Amgen","year":"2026"},{"key":"10.1016\/j.jconrel.2026.115431_bb0605","series-title":"Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological\/Biological Products","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use","year":"1999"},{"key":"10.1016\/j.jconrel.2026.115431_bb0610","author":"European Medicines Agency"},{"key":"10.1016\/j.jconrel.2026.115431_bb0615","author":"European Medicines Agency"},{"key":"10.1016\/j.jconrel.2026.115431_bb0620","series-title":"Handling of designation of Innovative Pharmaceutical Products under the SAKIGAKE system","author":"Ministry of Health, Labour and Welfare, Japan","year":"2023"},{"issue":"8","key":"10.1016\/j.jconrel.2026.115431_bb0625","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/nbt.3298","article-title":"Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown","volume":"33","author":"Wittrup","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115431_bb0630","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/nat.2022.0004","article-title":"Delivery of RNA therapeutics: the great endosomal escape!","volume":"32","author":"Dowdy","year":"2022","journal-title":"Nucleic Acid Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115431_bb0635","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1038\/s41467-020-15300-1","article-title":"Imaging small molecule-induced endosomal escape of siRNA","volume":"11","author":"Du Rietz","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115431_bb0640","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jconrel.2022.07.041","article-title":"Engineered ionizable lipid siRNA conjugates enhance endosomal escape but induce toxicity in vivo","volume":"349","author":"Biscans","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115431_bb0645","series-title":"QALSODY (Tofersen) Injection, Prescribing Information","author":"U.S. Food and Drug Administration","year":"2023"},{"key":"10.1016\/j.jconrel.2026.115431_bb0650","series-title":"National Institute for Health and Care Excellence: Technology Appraisals","article-title":"Eplontersen for treating hereditary transthyretin-related amyloidosis","author":"National Institute for Health and Care Excellence","year":"2024"},{"key":"10.1016\/j.jconrel.2026.115431_bb0655","series-title":"Inclisiran for Treating Primary Hypercholesterolaemia or Mixed Dyslipidaemia","author":"National Institute for Health and Care Excellence","year":"2021"},{"key":"10.1016\/j.jconrel.2026.115431_bb0660","series-title":"Funding and Supply of Inclisiran (Leqvio\u00ae)","author":"NHS England","year":"2025"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926008357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926008357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T09:51:07Z","timestamp":1793440267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926008357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":132,"alternative-id":["S0168365926008357"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115431","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delivery architectures for oligonucleotide therapeutics in genetic and rare diseases: GalNAc-based hepatocyte targeting and extrahepatic translation","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115431","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115431"}}